



Case Report

A Rare Case of Primary Mediastinal B-Cell Lymphoma – The Great Masquerade

Shamisha Shashank Khade¹, Manjiri Rajiv Naik¹

¹Department of Internal Medicine, MGM Medical College and Hospital, Aurangabad, Maharashtra, India.



***Corresponding author:**
Shamisha Shashank Khade,
Department of Internal
Medicine, MGM Medical
College and Hospital,
Aurangabad, Maharashtra, India.
shamishakhade@gmail.com

Received : 29 April 2022
Accepted : 24 June 2022
Published : 21 November 2022

DOI
[10.25259/ICAJ_4_2022](https://doi.org/10.25259/ICAJ_4_2022)

Quick Response Code:



ABSTRACT

Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly seen in young adults with female predominance. It constitutes approximately 2–4% of all non-Hodgkin's lymphomas (NHLs). No risk factors for this type have been identified but it may be related to 5533 C>A mutation in the MLL gene. Its molecular signature and clinical features resemble classical Hodgkin's lymphoma. PMBCL belongs to a group of aggressive diffuse large B-cell lymphomas. 2008 WHO classification distinguishes this lymphoma as a separate entity due to its specific clinical features and pathological features. Gene expression profile studies showed that it shares common features with classical Hodgkin's lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. Furthermore, no convincing data are supporting the use of radiotherapy. Relatively low patient numbers are the main obstacle in conducting randomised prospective trials. Hence, therapeutic decisions have been based mainly on retrospective studies.

Keywords: Primary mediastinal B-cell lymphoma, Non-Hodgkin's lymphoma, Positron emission tomography scan, Chemotherapy, Radiotherapy, MLL gene, Immunohistochemical examination

INTRODUCTION

Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly seen in young adults with female predominance.^[1-5] It constitutes approximately 2–4% of all non-Hodgkin's lymphomas (NHLs). No risk factors for this type have been identified but it may be related to 5533 C>A mutation in the MLL gene. Its molecular signature and clinical features resemble classical Hodgkin's lymphoma. PMBCL belongs to a group of aggressive diffuse large B-cell lymphomas.^[2,5,6] 2008 WHO classification distinguishes this lymphoma as a separate entity due to its specific clinical features and pathological features. Gene expression profile studies showed that it shares common features with classical Hodgkin's lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. Furthermore, no convincing data are supporting the use of radiotherapy. Relatively low patient numbers are the main obstacle in conducting randomised prospective trials. Hence, therapeutic decisions have been based mainly on retrospective studies.^[6-9]

CASE REPORT

We present the case of a 19-year-old female who came to MGM Hospital with complaints of breathlessness on exertion and cough for 2-weeks. On enquiring further, she gave a history of weight loss of around 10 kg in 3 months and on and off fever. On doing a Skiagram of the chest,




Figure 1: (a) Chest X-ray, (b) contrast-enhanced computed tomography chest, (c) positron emission tomography scan.




Figure 2: Vimentin-positive IHC biopsy specimen.

left sides shadow with blunting of costophrenic angle on the left side was seen with opacity in the left upper lobe suggestive of the left-sided pleural effusion and left upper lobe mass. An ultrasound (USG)-guided diagnostic and therapeutic pleural tap was done and around 200 ml of pleural fluid was tapped out. Infective aetiology was ruled out by running tests on the pleural fluid collected. This was followed by a contrast-enhanced computed tomography abdomen and chest for evaluation of the mass [Figure 1]. It revealed a neoplastic carcinomatous lesion of size 11.4 × 8.2 × 14.6 cm involving left upper lobe lung parenchyma with extension into the anterior mediastinum and enlarged necrotic prevascular and supraclavicular lymph nodes. The abdomen was clear suggestive of no metastasis to the abdomen. A USG-guided biopsy of the mass was performed and the sample underwent histopathological and immunohistochemical (IHC) examination which revealed a low-grade neoplasm and on running the IHC markers on it [Figure 2], the diagnosis of mediastinal B-cell NHL was made. A positron emission tomography (PET) scan was performed which showed increased uptake of FDG in the mediastinum and supraclavicular region [Figure 1]. The patient was started on

an R-CHOP regimen for NHL and is on the same treatment currently with 2 cycles of chemotherapy completed. A repeat PET scan will be performed after 6 cycles of chemotherapy to check the progression of the tumour.

CONCLUSION

Because PMBCL is uncommon, its clinical management varies across centres. There is no standard protocol for the treatment of PMBCL but chemotherapy R-CHOP and dose-adjusted E-POC regimen are shown to be beneficial. The role of radiotherapy is unclear. Recent research has brought new insight into molecular mechanisms contributing to the malignant phenotype of PMBCL and this could direct the development of targeted therapies.

Declaration of patient consent

Patient's consent not required as patient's identity is not disclosed or compromised.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, *et al.*, editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008. p. 250-1.
2. Gerrard M, Waxman IM, Sposto R, Auperin A, Perkins SL, Goldman S, *et al.* Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. *Blood* 2013;121:278-85.
3. Saarinen S, Kaasinen E, Karjalainen-Lindsberg ML, Vesanen K, Aavikko M, Katainen R, *et al.* Primary mediastinal large B-cell lymphoma segregating in a family: Exome sequencing identifies MLL as a candidate predisposition gene. *Blood* 2013;121:3428-30.
4. Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, *et al.* Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. *Haematologica* 2002;87:1258-64.
5. Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. *Hematol Am Soc Hematol Educ Program* 2008;2008:349-58.
6. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, *et al.* Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. *Ann Oncol* 2006;17:122-30.
7. Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, *et al.* Novel prognostic model of Primary Mediastinal Large B-cell Lymphoma (PMBL): A multicenter cooperative

- retrospective study in Japan. *Blood* 2013;122:638.
8. Hamlin PA, Portlock CS, Strauss DJ, Noy A, Singer A, Horwitz SM, *et al.* Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. *Br J Haematol* 2005;130:691-9.
 9. Harris NL. Shades of grey between large B-cell lymphomas

and Hodgkin lymphomas: Differential diagnosis and biological implications. *Mod Pathol* 2013;26 Suppl 1:S57-70.

How to cite this article: Khade SS, Naik MR. A rare case of primary mediastinal B-cell lymphoma – The great masquerade. *Indian Cancer Awareness J* 2022;1:59-61.